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background: Surgical valve replacement is the treatment of choice for patients with non-rheumatic mitral stenosis (MS). While there have been 
reports of successful percutaneous balloon mitral valvuloplasty (PBMV) in MS due to mitral annular calcification that impinges on the mitral orifice, 
PBMV is typically reserved for rheumatic MS with favorable valve morphology. Patients with severe, non-rheumatic MS who are deemed non-operable 
present a challenging clinical dilemma due to limited conservative treatment options.
case:  An 89-year-old woman with severe, non-rheumatic MS due to mitral annular calcification presented with several weeks of worsening dyspnea 
and acute renal failure. Her previously rate-controlled atrial fibrillation was now complicated by rapid ventricular response. Physical examination 
showed signs of low output with congestion: cool extremities, faint peripheral pulses, bibasilar crackles, and intermittent confusion. Six months ago, 
her mean mitral valve gradient was 22 mmHg, with a valve area of 0.93 cm2, but surgical intervention was deferred due to prohibitive risk.
Decision-making:  Repeat transthoracic echocardiogram on admission showed a mean mitral valve gradient of 18 mmHg, with a valve area of 
0.5 cm2. Beta blockers were titrated in an attempt to improve diastolic filling, but this led to intermittent hypotension. AV nodal ablation with VVI 
pacing at 55 beats per minute was then attempted, but failed to improve either her symptoms or renal function. After extensive discussion with 
family, the decision was made to pursue PBMV despite her unfavorable valve anatomy. Valvuloplasty resulted in a reduction in mean valve gradient 
from 22 to 9 mm Hg. Calculated valve area post-procedure was 1.3 cm2. Her systolic blood pressures rose from the 90’s to the 130’s, and her 
symptoms significantly improved. After several days of physical therapy, she walked out of the hospital under her own power.
conclusion: PBMV may be an option for palliative treatment of non-operable patients with severe, non-rheumatic mitral stenosis due to mitral 
annular calcification that impinges on the mitral orifice.
